Sera Prognostics Net Income From Continuing Ops Over Time
| SERA Stock | USD 8.60 0.18 2.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sera Prognostics Performance and Sera Prognostics Correlation. Sera |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sera Prognostics. If investors know Sera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sera Prognostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 0.003 | Quarterly Revenue Growth (0.31) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Sera Prognostics is measured differently than its book value, which is the value of Sera that is recorded on the company's balance sheet. Investors also form their own opinion of Sera Prognostics' value that differs from its market value or its book value, called intrinsic value, which is Sera Prognostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sera Prognostics' market value can be influenced by many factors that don't directly affect Sera Prognostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sera Prognostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sera Prognostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sera Prognostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Sera Prognostics and related stocks such as Fate Therapeutics, Sana Biotechnology, and Caribou Biosciences Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE | (20.9 M) | (20.9 M) | (20.9 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (281.7 M) | (173.2 M) | (164.5 M) |
| SANA | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (130.8 M) | (285.3 M) | (355.9 M) | (269.5 M) | (283.3 M) | (297.4 M) |
| CRBU | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (23.4 M) | (34.3 M) | (66.9 M) | (99.4 M) | (94.6 M) | (99.3 M) |
| RCUS | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (53.1 M) | (49.6 M) | (84.7 M) | (122.9 M) | 52.8 M | (267 M) | (307 M) | (291.6 M) |
| KPTI | (33.9 M) | (33.9 M) | (33.9 M) | (33.9 M) | (75.8 M) | (118.2 M) | (109.6 M) | (129 M) | (178.4 M) | (199.6 M) | (196.3 M) | (124.1 M) | (165.3 M) | (139.8 M) | (146.8 M) |
| XFOR | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (23 M) | (33.9 M) | (43 M) | (52.8 M) | (62.1 M) | (88.7 M) | (93.9 M) | (111.1 M) | (105.6 M) |
| HOOK | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (16.2 M) | (43 M) | (44.1 M) | (75.7 M) | (64.9 M) | (69.1 M) | (72.5 M) |
Sera Prognostics and related stocks such as Fate Therapeutics, Sana Biotechnology, and Caribou Biosciences Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Sera Prognostics | SERA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Utah; U.S.A |
| Exchange | NASDAQ Exchange |
USD 8.6
Check out Sera Prognostics Performance and Sera Prognostics Correlation. For information on how to trade Sera Stock refer to our How to Trade Sera Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Sera Prognostics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.